Our platforms use cutting edge computational and synthetic biology to discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets
We apply the following approaches on metagenomic and metatranscriptomicdata to pinpoint harmful bacteria linked to disease states
Strain Level Relative Abundance
Bacterial Growth Dynamics
RNA Level Response To Stimuli
Develop customized phage therapies that seek and destroy harmful bacteria targets
THE PHAGE DISCOVERY PROCESS IS COMPRISED OF:
Proprietary assays and processes for pre-clinical and clinical development of our pipeline products.
Our first project to demonstrate pre-clinical development of customized phage therapies addresses acne and is comprised of naturally occurring phages capable of eradicating P. acnes, which is a main cause of acne. The phage therapy does not affect other bacteria beneficial to the skin and has demonstrated efficient eradication of a broad host range of P. acne bacteria lines, including antibiotic resistant lines. cGMP manufacture is underway and preclinical development has commenced.
Our discovery platform for predictive microbiome-based biomarkers